Loading…
PT Anugerah Lestari Abadi received an FDA Warning Letter on January 9, 2018, though the specific product category and violation details are not available in the provided metadata. Based on the limited information available, the letter was issued by the FDA but the specific issuing office and subject matter cannot be determined from the metadata alone. Without access to the full warning letter text, the precise nature of the regulatory violations and the company's product category remain unclear. This summary should be supplemented with the complete warning letter for accurate regulatory intelligence.